Evaluation of serum amyloid a as a biomarker for gastric cancer

De-Chuan Chan, Cheng-Jueng Chen, Heng-Cheng Chu, Wei-Kuo Chang, Jyh-Cherng Yu, Yu-Ju Chen, Li-Li Wen, Su-Ching Huang, Chih-Hung Ku, Yao-Chi Liu, Jenn-Han Chen

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Background: Serum amyloid A (SAA) is a useful biomarker for gastric cancer in an animal model. We investigated the potential of SAA as a biomarker for gastric cancer in humans. Methods: Serum levels of SAA from 96 gastric cancer patients were measured before and after curative gastrectomy; 32 patients with gastric ulcers and 52 healthy subjects were the control groups. The immunohistochemical study was performed to evaluate the protein expression over gastric cancer tissue slides. Results: The mean SAA concentration was higher in gastric cancer patients (88.54 ± 50.44 mg/l) than in healthy subjects (3.36 ± 2.29 mg/l) and gastric ulcer patients (10.48 ± 8.97 mg/l) (P <.05). The SAA concentration was associated with tumor stage (P = .0244) and location (P = .0016) but not with Lauren's histological type (P = .839). In the multivariate analysis, SAA level was correlated with tumor location (P <.0001) and lymph node status (P <.05). During follow-up, the mean SAA concentration increased significantly in 24 patients with tumor recurrence (P <.05) but did not change in 77 patients without recurrence. In the survival analysis, patients with SAA levels > 97 mg/l had a nearly fourfold increase in risk of death. Immunoreactivity was most prominent in blood vessel regions but not within cancer cells. Conclusions: These data not only demonstrated SAA was useful in predicting survival of patients with gastric cancer, but they also showed that SAA was a valuable tool for postoperative follow-up. © 2006 Society of Surgical Oncology.
Original languageEnglish
Pages (from-to)84-93
Number of pages10
JournalAnnals of Surgical Oncology
Volume14
Issue number1
DOIs
Publication statusPublished - 2007
Externally publishedYes

Fingerprint

Serum Amyloid A Protein
Amyloid
Stomach Neoplasms
Biomarkers
Serum
Stomach Ulcer
Healthy Volunteers
Gastrectomy
Blood Vessels
Animal Models
Control Groups
Survival
Neoplasms
Proteins

Keywords

  • Mass spectrometry (MS)
  • Serum amyloid A (SAA) protein
  • Serum marker
  • Stomach neoplasm
  • biological marker
  • serum amyloid A
  • article
  • blood vessel
  • cancer cell
  • cancer patient
  • cancer survival
  • concentration response
  • controlled study
  • correlation analysis
  • disease marker
  • evaluation
  • follow up
  • gastrectomy
  • human
  • human tissue
  • immunohistochemistry
  • immunoreactivity
  • lymph node
  • major clinical study
  • measurement
  • mortality
  • multivariate analysis
  • protein expression
  • stomach cancer
  • stomach ulcer
  • tissue section
  • tumor recurrence
  • Adenocarcinoma
  • Aged
  • Female
  • Gastrectomy
  • Humans
  • Immunohistochemistry
  • Male
  • Middle Aged
  • Serum Amyloid A Protein
  • Stomach Neoplasms
  • Stomach Ulcer
  • Survival Analysis
  • Tumor Markers, Biological

Cite this

Chan, D-C., Chen, C-J., Chu, H-C., Chang, W-K., Yu, J-C., Chen, Y-J., ... Chen, J-H. (2007). Evaluation of serum amyloid a as a biomarker for gastric cancer. Annals of Surgical Oncology, 14(1), 84-93. https://doi.org/10.1245/s10434-006-9091-z

Evaluation of serum amyloid a as a biomarker for gastric cancer. / Chan, De-Chuan; Chen, Cheng-Jueng; Chu, Heng-Cheng; Chang, Wei-Kuo; Yu, Jyh-Cherng; Chen, Yu-Ju; Wen, Li-Li; Huang, Su-Ching; Ku, Chih-Hung; Liu, Yao-Chi; Chen, Jenn-Han.

In: Annals of Surgical Oncology, Vol. 14, No. 1, 2007, p. 84-93.

Research output: Contribution to journalArticle

Chan, D-C, Chen, C-J, Chu, H-C, Chang, W-K, Yu, J-C, Chen, Y-J, Wen, L-L, Huang, S-C, Ku, C-H, Liu, Y-C & Chen, J-H 2007, 'Evaluation of serum amyloid a as a biomarker for gastric cancer', Annals of Surgical Oncology, vol. 14, no. 1, pp. 84-93. https://doi.org/10.1245/s10434-006-9091-z
Chan, De-Chuan ; Chen, Cheng-Jueng ; Chu, Heng-Cheng ; Chang, Wei-Kuo ; Yu, Jyh-Cherng ; Chen, Yu-Ju ; Wen, Li-Li ; Huang, Su-Ching ; Ku, Chih-Hung ; Liu, Yao-Chi ; Chen, Jenn-Han. / Evaluation of serum amyloid a as a biomarker for gastric cancer. In: Annals of Surgical Oncology. 2007 ; Vol. 14, No. 1. pp. 84-93.
@article{5d84b6c9560b405abea6c5ee6eb6648a,
title = "Evaluation of serum amyloid a as a biomarker for gastric cancer",
abstract = "Background: Serum amyloid A (SAA) is a useful biomarker for gastric cancer in an animal model. We investigated the potential of SAA as a biomarker for gastric cancer in humans. Methods: Serum levels of SAA from 96 gastric cancer patients were measured before and after curative gastrectomy; 32 patients with gastric ulcers and 52 healthy subjects were the control groups. The immunohistochemical study was performed to evaluate the protein expression over gastric cancer tissue slides. Results: The mean SAA concentration was higher in gastric cancer patients (88.54 ± 50.44 mg/l) than in healthy subjects (3.36 ± 2.29 mg/l) and gastric ulcer patients (10.48 ± 8.97 mg/l) (P <.05). The SAA concentration was associated with tumor stage (P = .0244) and location (P = .0016) but not with Lauren's histological type (P = .839). In the multivariate analysis, SAA level was correlated with tumor location (P <.0001) and lymph node status (P <.05). During follow-up, the mean SAA concentration increased significantly in 24 patients with tumor recurrence (P <.05) but did not change in 77 patients without recurrence. In the survival analysis, patients with SAA levels > 97 mg/l had a nearly fourfold increase in risk of death. Immunoreactivity was most prominent in blood vessel regions but not within cancer cells. Conclusions: These data not only demonstrated SAA was useful in predicting survival of patients with gastric cancer, but they also showed that SAA was a valuable tool for postoperative follow-up. {\circledC} 2006 Society of Surgical Oncology.",
keywords = "Mass spectrometry (MS), Serum amyloid A (SAA) protein, Serum marker, Stomach neoplasm, biological marker, serum amyloid A, article, blood vessel, cancer cell, cancer patient, cancer survival, concentration response, controlled study, correlation analysis, disease marker, evaluation, follow up, gastrectomy, human, human tissue, immunohistochemistry, immunoreactivity, lymph node, major clinical study, measurement, mortality, multivariate analysis, protein expression, stomach cancer, stomach ulcer, tissue section, tumor recurrence, Adenocarcinoma, Aged, Female, Gastrectomy, Humans, Immunohistochemistry, Male, Middle Aged, Serum Amyloid A Protein, Stomach Neoplasms, Stomach Ulcer, Survival Analysis, Tumor Markers, Biological",
author = "De-Chuan Chan and Cheng-Jueng Chen and Heng-Cheng Chu and Wei-Kuo Chang and Jyh-Cherng Yu and Yu-Ju Chen and Li-Li Wen and Su-Ching Huang and Chih-Hung Ku and Yao-Chi Liu and Jenn-Han Chen",
note = "被引用次數:54 Export Date: 22 March 2016 CODEN: ASONF 通訊地址: Chan, D.-C.; Division of General Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan; 電子郵件: chrischan1168@yahoo.com.tw 化學物質/CAS: Serum Amyloid A Protein; Tumor Markers, Biological 參考文獻: Stadtlander, C.T., Waterbor, J.W., Molecular epidemiology, pathogenesis and prevention of gastric cancer (1999) Carcinogenesis, 20, pp. 2195-2208; (1997) Health and Vital Statistics, , Taipei: Department of Health, Executive Yuan, Republic of China; Collard, J.M., Malaise, J., Mabrut, J.Y., Skeletonizing. En-bloc gastrectomy for adenocarcinoma in Caucasian patients (2003) Gastric Cancer, 6, pp. 210-216; Juan, H.F., Chen, J.H., Hsu, W.T., Identification of tumor-associated plasma biomarkers using proteomic techniques: From mouse to human (2004) Proteomics, 4, pp. 2766-2775; Sheu, L.F., Chen, A., Wei, Y.H., Epstein-Barr virus LMP1 modulates the malignant potential of gastric carcinoma cells involving apoptosis (1998) Am J Pathol, 152, pp. 63-74; Yamada, T., Serum amyloid a (SAA): A concise review of biology, assay methods and clinical usefulness (1999) Clin Chem Lab Med, 37, pp. 381-388; Biran, H., Friedman, N., Neumann, P.M., Serum amyloid a (SAA) variations in patients with cancer: Correlation with disease activity, stage, primary site, and prognosis (1986) J Clin Pathol, 39, pp. 794-797; Kimura, M., Tomita, Y., Imai, T., Significance of serum amyloid A on the prognosis in patients with renal cell carcinoma (2001) Cancer, 92 (8), pp. 2072-2075; Glojnaric, I., Casl, M.T., Simic, D., Serum amyloid A protein (SAA) in colorectal carcinoma (2001) Clin Chem Lab Med, 39 (2), pp. 129-133; Kaneti, J., Winikoff, Y., Zimlichman, S., Importance of serum amyloid A (SAA) level in monitoring disease activity and response to therapy in patients with prostate cancer (1984) Urol Res, 12 (5), pp. 239-241; Cho, W.C., Yip, T.T., Yip, C., Identification of serum amyloid a protein as a potentially useful biomarker to monitor relapse of nasopharyngeal cancer by serum proteomic profiling (2004) Clin Cancer Res, 10 (1 PART 1), pp. 43-52; O'Hanlon, D.M., Lynch, J., Cormican, M., Given, H.F., The acute phase response in breast carcinoma (2002) Anticancer Res, 22, pp. 1289-1293; Rosenthal, C.J., Sullivan, L.M., Serum amyloid A to monitor cancer dissemination (1979) Ann Intern Med, 91, pp. 383-390; (1993) The General Rules for the Gastric Cancer Study. 12th Edn., pp. 30-33. , Japanese Research Society for Gastric Cancer. Tokyo: Kanehara; Sobin, L.H., Wittekind, C.H., (1997) International Union Against Cancer (UICC): TNM Classification of Malignant Tumors, 5th Edn., , New York: John Wiley; Lauren, P., The two histological main types of gastric carcinoma: Diffuse and so-called intestinal-type carcinoma (1965) Acta Pathol Microbiol Scand, 64, pp. 31-49; Juan, H.F., Lin, J.Y., Chang, W.H., Biomic study of human myeloid leukemia cells differentiation to macrophages using DNA array, proteomic, and bioinformatics analytical methods (2002) Electrophoresis, 23, pp. 2490-2504; D'Eril, G.M., Anesi, A., Maggiore, M., Biological variation of serum amyloid A in healthy subjects (2001) Clin Chem, 47, pp. 1498-1499; Shimizu, N., Wakatsuki, T., Murakami, A., Carcinoembryonic antigen in gastric cancer patients (1987) Oncology, 44, pp. 240-244; Nakane, Y., Okamura, S., Akehira, K., Correlation of preoperative carcinoembryonic antigen levels and prognosis of gastric cancer patients (1994) Cancer, 73, pp. 2703-2708; Koga, T., Kano, T., Souda, K., The clinical usefulness of preoperative CEA determination in gastric cancer (1987) Jpn J Surg, 17, pp. 342-347; Sakamoto, K., Haga, Y., Yoshimura, R., Comparative effectiveness of the tumour diagnostics, CA 19-9, CA125 and carcinoembryonic antigen in patients with diseases of the digestive system (1987) Gut, 28, pp. 323-329; Marrelli, D., Roviello, F., De Stefano, A., Prognostic significance of CEA, CA 19-9 and CA 72-4 preoperative serum levels in gastric carcinoma (1999) Oncology, 57, pp. 55-62; Safi, F., Kuhns, V., Beger, H.G., Comparison of CA72-4, CA19-9 and CEA in the diagnosis and monitoring of gastric cancer (1995) Int J Biol Markers, 10, pp. 100-106; Parsonnet, J., Friedman, G.D., Vandersteen, D.P., Helicobacter pylori infection and the risk of gastric carcinoma (1991) N Engl J Med, 325, pp. 1127-1131; Forman, D., Newell, D.G., Fullerton, F., Association between infection with Helicobacter pylori and risk of gastric cancer: Evidence from a prospective investigation (1991) BMJ, 302, pp. 1302-1305; Hansen, S., Melby, K.K., Aase, S., Jellium, E., Vollset, S.E., Helicobacter pylori infection and risk of cardia cancer and non-cardia cancer (1999) Scand J Gastroenterol, 4, pp. 353-360; Delanghe, J.R., Langlois, M.R., De Bacquer, D., Mak, R., Capel, P., Van Renterghem, L., De Backer, G., Discriminative value of serum amyloid A and other acute-phase proteins for coronary heart disease (2002) Atherosclerosis, 160 (2), pp. 471-476; Hagihara, K., Nishikawa, T., Isobe, T., IL-6 plays a critical role in the synergistic induction of human serum amyloid A (SAA) gene when stimulated with proinflammatory cytokines as analyzed with an SAA isoform real-time quantitative RT-PCR assay system (2004) Biochem Biophys Res Commun, 314 (2), pp. 363-369; Galizia, G., Lieto, E., De Vita, F., Circulating levels of interleukin-10 and interleukin-6 in gastric and colon cancer patients before and after surgery: Relationship with radicality and outcome (2002) J Interferon Cytokine Res, 22, pp. 473-482; Yamaoka, Y., Kodama, T., Kita, M., Relation between cytokines and Helicobacter pylori in gastric cancer (2001) Helicobacter, 6, pp. 116-124; De Vita, F., Romano, C., Orditura, M., Interleukin-6 serum level correlates with survival in advanced gastrointestinal cancer patients but is not an independent prognostic indicator (2001) J Interferon Cytokine Res, 21, pp. 45-52; Wu, C.W., Wang, S.R., Chao, M.F., Serum interleukin-6 levels reflect disease status of gastric cancer (1996) Am J Gastroenterol, 91, pp. 1417-1422; Kabir, S., Daar, G.A., Serum levels of interleukin-1, interleukin-6 and tumor necrosis factor-alpha in patients with gastric cancer (1995) Cancer Lett, 95, pp. 207-212; Tatsuno, I., Nishikawa, T., Sasano, H., Interleukin 6-producing gastric carcinoma with fever, hypergammaglobulinemia, and plasmacytosis in bone marrow (1994) Gastroenterology, 107, pp. 543-547; Lin, M.T., Juan, C.Y., Chang, K.J., IL-6 inhibits apoptosis and retains oxidative DNA lesions in human gastric cancer AGS cells through up-regulation of anti-apoptotic gene mcl-1 (2001) Carcinogenesis, 22, pp. 1947-1953; Ding, S.Z., Cho, C.H., Lam, S.K., Regulation of IL-6 production in human gastric epithelial cell line MKN-28 (2000) Cytokine, 12, pp. 1129-1135",
year = "2007",
doi = "10.1245/s10434-006-9091-z",
language = "English",
volume = "14",
pages = "84--93",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Evaluation of serum amyloid a as a biomarker for gastric cancer

AU - Chan, De-Chuan

AU - Chen, Cheng-Jueng

AU - Chu, Heng-Cheng

AU - Chang, Wei-Kuo

AU - Yu, Jyh-Cherng

AU - Chen, Yu-Ju

AU - Wen, Li-Li

AU - Huang, Su-Ching

AU - Ku, Chih-Hung

AU - Liu, Yao-Chi

AU - Chen, Jenn-Han

N1 - 被引用次數:54 Export Date: 22 March 2016 CODEN: ASONF 通訊地址: Chan, D.-C.; Division of General Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan; 電子郵件: chrischan1168@yahoo.com.tw 化學物質/CAS: Serum Amyloid A Protein; Tumor Markers, Biological 參考文獻: Stadtlander, C.T., Waterbor, J.W., Molecular epidemiology, pathogenesis and prevention of gastric cancer (1999) Carcinogenesis, 20, pp. 2195-2208; (1997) Health and Vital Statistics, , Taipei: Department of Health, Executive Yuan, Republic of China; Collard, J.M., Malaise, J., Mabrut, J.Y., Skeletonizing. En-bloc gastrectomy for adenocarcinoma in Caucasian patients (2003) Gastric Cancer, 6, pp. 210-216; Juan, H.F., Chen, J.H., Hsu, W.T., Identification of tumor-associated plasma biomarkers using proteomic techniques: From mouse to human (2004) Proteomics, 4, pp. 2766-2775; Sheu, L.F., Chen, A., Wei, Y.H., Epstein-Barr virus LMP1 modulates the malignant potential of gastric carcinoma cells involving apoptosis (1998) Am J Pathol, 152, pp. 63-74; Yamada, T., Serum amyloid a (SAA): A concise review of biology, assay methods and clinical usefulness (1999) Clin Chem Lab Med, 37, pp. 381-388; Biran, H., Friedman, N., Neumann, P.M., Serum amyloid a (SAA) variations in patients with cancer: Correlation with disease activity, stage, primary site, and prognosis (1986) J Clin Pathol, 39, pp. 794-797; Kimura, M., Tomita, Y., Imai, T., Significance of serum amyloid A on the prognosis in patients with renal cell carcinoma (2001) Cancer, 92 (8), pp. 2072-2075; Glojnaric, I., Casl, M.T., Simic, D., Serum amyloid A protein (SAA) in colorectal carcinoma (2001) Clin Chem Lab Med, 39 (2), pp. 129-133; Kaneti, J., Winikoff, Y., Zimlichman, S., Importance of serum amyloid A (SAA) level in monitoring disease activity and response to therapy in patients with prostate cancer (1984) Urol Res, 12 (5), pp. 239-241; Cho, W.C., Yip, T.T., Yip, C., Identification of serum amyloid a protein as a potentially useful biomarker to monitor relapse of nasopharyngeal cancer by serum proteomic profiling (2004) Clin Cancer Res, 10 (1 PART 1), pp. 43-52; O'Hanlon, D.M., Lynch, J., Cormican, M., Given, H.F., The acute phase response in breast carcinoma (2002) Anticancer Res, 22, pp. 1289-1293; Rosenthal, C.J., Sullivan, L.M., Serum amyloid A to monitor cancer dissemination (1979) Ann Intern Med, 91, pp. 383-390; (1993) The General Rules for the Gastric Cancer Study. 12th Edn., pp. 30-33. , Japanese Research Society for Gastric Cancer. Tokyo: Kanehara; Sobin, L.H., Wittekind, C.H., (1997) International Union Against Cancer (UICC): TNM Classification of Malignant Tumors, 5th Edn., , New York: John Wiley; Lauren, P., The two histological main types of gastric carcinoma: Diffuse and so-called intestinal-type carcinoma (1965) Acta Pathol Microbiol Scand, 64, pp. 31-49; Juan, H.F., Lin, J.Y., Chang, W.H., Biomic study of human myeloid leukemia cells differentiation to macrophages using DNA array, proteomic, and bioinformatics analytical methods (2002) Electrophoresis, 23, pp. 2490-2504; D'Eril, G.M., Anesi, A., Maggiore, M., Biological variation of serum amyloid A in healthy subjects (2001) Clin Chem, 47, pp. 1498-1499; Shimizu, N., Wakatsuki, T., Murakami, A., Carcinoembryonic antigen in gastric cancer patients (1987) Oncology, 44, pp. 240-244; Nakane, Y., Okamura, S., Akehira, K., Correlation of preoperative carcinoembryonic antigen levels and prognosis of gastric cancer patients (1994) Cancer, 73, pp. 2703-2708; Koga, T., Kano, T., Souda, K., The clinical usefulness of preoperative CEA determination in gastric cancer (1987) Jpn J Surg, 17, pp. 342-347; Sakamoto, K., Haga, Y., Yoshimura, R., Comparative effectiveness of the tumour diagnostics, CA 19-9, CA125 and carcinoembryonic antigen in patients with diseases of the digestive system (1987) Gut, 28, pp. 323-329; Marrelli, D., Roviello, F., De Stefano, A., Prognostic significance of CEA, CA 19-9 and CA 72-4 preoperative serum levels in gastric carcinoma (1999) Oncology, 57, pp. 55-62; Safi, F., Kuhns, V., Beger, H.G., Comparison of CA72-4, CA19-9 and CEA in the diagnosis and monitoring of gastric cancer (1995) Int J Biol Markers, 10, pp. 100-106; Parsonnet, J., Friedman, G.D., Vandersteen, D.P., Helicobacter pylori infection and the risk of gastric carcinoma (1991) N Engl J Med, 325, pp. 1127-1131; Forman, D., Newell, D.G., Fullerton, F., Association between infection with Helicobacter pylori and risk of gastric cancer: Evidence from a prospective investigation (1991) BMJ, 302, pp. 1302-1305; Hansen, S., Melby, K.K., Aase, S., Jellium, E., Vollset, S.E., Helicobacter pylori infection and risk of cardia cancer and non-cardia cancer (1999) Scand J Gastroenterol, 4, pp. 353-360; Delanghe, J.R., Langlois, M.R., De Bacquer, D., Mak, R., Capel, P., Van Renterghem, L., De Backer, G., Discriminative value of serum amyloid A and other acute-phase proteins for coronary heart disease (2002) Atherosclerosis, 160 (2), pp. 471-476; Hagihara, K., Nishikawa, T., Isobe, T., IL-6 plays a critical role in the synergistic induction of human serum amyloid A (SAA) gene when stimulated with proinflammatory cytokines as analyzed with an SAA isoform real-time quantitative RT-PCR assay system (2004) Biochem Biophys Res Commun, 314 (2), pp. 363-369; Galizia, G., Lieto, E., De Vita, F., Circulating levels of interleukin-10 and interleukin-6 in gastric and colon cancer patients before and after surgery: Relationship with radicality and outcome (2002) J Interferon Cytokine Res, 22, pp. 473-482; Yamaoka, Y., Kodama, T., Kita, M., Relation between cytokines and Helicobacter pylori in gastric cancer (2001) Helicobacter, 6, pp. 116-124; De Vita, F., Romano, C., Orditura, M., Interleukin-6 serum level correlates with survival in advanced gastrointestinal cancer patients but is not an independent prognostic indicator (2001) J Interferon Cytokine Res, 21, pp. 45-52; Wu, C.W., Wang, S.R., Chao, M.F., Serum interleukin-6 levels reflect disease status of gastric cancer (1996) Am J Gastroenterol, 91, pp. 1417-1422; Kabir, S., Daar, G.A., Serum levels of interleukin-1, interleukin-6 and tumor necrosis factor-alpha in patients with gastric cancer (1995) Cancer Lett, 95, pp. 207-212; Tatsuno, I., Nishikawa, T., Sasano, H., Interleukin 6-producing gastric carcinoma with fever, hypergammaglobulinemia, and plasmacytosis in bone marrow (1994) Gastroenterology, 107, pp. 543-547; Lin, M.T., Juan, C.Y., Chang, K.J., IL-6 inhibits apoptosis and retains oxidative DNA lesions in human gastric cancer AGS cells through up-regulation of anti-apoptotic gene mcl-1 (2001) Carcinogenesis, 22, pp. 1947-1953; Ding, S.Z., Cho, C.H., Lam, S.K., Regulation of IL-6 production in human gastric epithelial cell line MKN-28 (2000) Cytokine, 12, pp. 1129-1135

PY - 2007

Y1 - 2007

N2 - Background: Serum amyloid A (SAA) is a useful biomarker for gastric cancer in an animal model. We investigated the potential of SAA as a biomarker for gastric cancer in humans. Methods: Serum levels of SAA from 96 gastric cancer patients were measured before and after curative gastrectomy; 32 patients with gastric ulcers and 52 healthy subjects were the control groups. The immunohistochemical study was performed to evaluate the protein expression over gastric cancer tissue slides. Results: The mean SAA concentration was higher in gastric cancer patients (88.54 ± 50.44 mg/l) than in healthy subjects (3.36 ± 2.29 mg/l) and gastric ulcer patients (10.48 ± 8.97 mg/l) (P <.05). The SAA concentration was associated with tumor stage (P = .0244) and location (P = .0016) but not with Lauren's histological type (P = .839). In the multivariate analysis, SAA level was correlated with tumor location (P <.0001) and lymph node status (P <.05). During follow-up, the mean SAA concentration increased significantly in 24 patients with tumor recurrence (P <.05) but did not change in 77 patients without recurrence. In the survival analysis, patients with SAA levels > 97 mg/l had a nearly fourfold increase in risk of death. Immunoreactivity was most prominent in blood vessel regions but not within cancer cells. Conclusions: These data not only demonstrated SAA was useful in predicting survival of patients with gastric cancer, but they also showed that SAA was a valuable tool for postoperative follow-up. © 2006 Society of Surgical Oncology.

AB - Background: Serum amyloid A (SAA) is a useful biomarker for gastric cancer in an animal model. We investigated the potential of SAA as a biomarker for gastric cancer in humans. Methods: Serum levels of SAA from 96 gastric cancer patients were measured before and after curative gastrectomy; 32 patients with gastric ulcers and 52 healthy subjects were the control groups. The immunohistochemical study was performed to evaluate the protein expression over gastric cancer tissue slides. Results: The mean SAA concentration was higher in gastric cancer patients (88.54 ± 50.44 mg/l) than in healthy subjects (3.36 ± 2.29 mg/l) and gastric ulcer patients (10.48 ± 8.97 mg/l) (P <.05). The SAA concentration was associated with tumor stage (P = .0244) and location (P = .0016) but not with Lauren's histological type (P = .839). In the multivariate analysis, SAA level was correlated with tumor location (P <.0001) and lymph node status (P <.05). During follow-up, the mean SAA concentration increased significantly in 24 patients with tumor recurrence (P <.05) but did not change in 77 patients without recurrence. In the survival analysis, patients with SAA levels > 97 mg/l had a nearly fourfold increase in risk of death. Immunoreactivity was most prominent in blood vessel regions but not within cancer cells. Conclusions: These data not only demonstrated SAA was useful in predicting survival of patients with gastric cancer, but they also showed that SAA was a valuable tool for postoperative follow-up. © 2006 Society of Surgical Oncology.

KW - Mass spectrometry (MS)

KW - Serum amyloid A (SAA) protein

KW - Serum marker

KW - Stomach neoplasm

KW - biological marker

KW - serum amyloid A

KW - article

KW - blood vessel

KW - cancer cell

KW - cancer patient

KW - cancer survival

KW - concentration response

KW - controlled study

KW - correlation analysis

KW - disease marker

KW - evaluation

KW - follow up

KW - gastrectomy

KW - human

KW - human tissue

KW - immunohistochemistry

KW - immunoreactivity

KW - lymph node

KW - major clinical study

KW - measurement

KW - mortality

KW - multivariate analysis

KW - protein expression

KW - stomach cancer

KW - stomach ulcer

KW - tissue section

KW - tumor recurrence

KW - Adenocarcinoma

KW - Aged

KW - Female

KW - Gastrectomy

KW - Humans

KW - Immunohistochemistry

KW - Male

KW - Middle Aged

KW - Serum Amyloid A Protein

KW - Stomach Neoplasms

KW - Stomach Ulcer

KW - Survival Analysis

KW - Tumor Markers, Biological

U2 - 10.1245/s10434-006-9091-z

DO - 10.1245/s10434-006-9091-z

M3 - Article

VL - 14

SP - 84

EP - 93

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 1

ER -